Expert Drug Evaluation
CHDR is co-founder of EDEN, the Expert Drug Evaluation Network
Drug development requires a coordinated collaboration among various disciplines. CHDR has formed a close-knit international network of renowned experts and organizations that cover the entire drug development process. The Expert Drug Evaluation Network (eden) includes experienced consultants in different aspects of drug development (from formulation to registration), various specialized biomarker laboratories, preclinical service organizations, drug manufacturing services, and clinical facilities for drug studies in healthy volunteers and patients.
The eden concept has been developed by CHDR to provide useful families of related services that are grouped to provide services in a certain area. The area of neuropsychopharmacology is covered by the edencns network. For vascular medicine we use edencvs. With the eden name we also indicate that all partners have been selected to the highest standards of scientific, ethical and operational standards. You will find commercial CRO’s, as well as University medical centres with certain capabilities.
Our clients and relations demand a tailored mix of expertise for their valuable projects. The eden family provides this with low overhead costs but at a quality that is unsurpassed
Edencns, accelerated proof of concept in neurology, psychiatry and pain
edencns offers drug development services for central nervous system indications. CHDR has partnered with top-level academic and contract research organisations that specialize in neurology, psychiatry and pain, to perform highly efficient studies in healthy subjects and patients with diseases of the central nervous system. edencns offers a unique integration of the entire process, from the first administration of a new drug to humans, until the proof of its therapeutic concept in patients. Each step of the process is integrated, by making optimal use of validated biomarkers of drug action and advanced pharmacometric analyses each study. These strategies can be smoothly incorporated in traditional early drug development studies, with the best possible study efficiency. It is also possible to use innovative designs, umbrella protocols and parallel trials to improve the information and speed of the proof of concept phase. Each year, edencns recruits more than a thousand healthy subjects and patients with conditions like schizophrenia, depression, dementia and neuropathic pain in phase I-IIb studies. See http://www.edencns.com/ for more information.
No single organisation can supply sufficient knowledge to support the breadth of areas in drug development. The network of consultants we employ are all contracted under the eden concept. Contrary to the many single person consultancies in drug development the edenconsultancy group has access to joint library and database facilities and is supported by a group of juniors and administrative staff. The network therefore can generally provide advise in most areas by highly experienced consultants. The client works with only one contract and does not have to pay for expensive overhead. edenconsultancy provides scientific advice both in the preclinical area and about clinical development. Regulatory advice and submissions and consultations with EMA and FDA can be arranged by our regulatory consultants.